DEA Marijuana Rescheduling Delay Raises Stakes for Industry and Patients

Timeline Slips Beyond Election Cycle

The DEA's proposed rule to move marijuana from Schedule I to Schedule III under the Controlled Substances Act now faces a timeline extending into early 2027, according to procedural analysis of the administrative rulemaking process. The agency published its Notice of Proposed Rulemaking (NPRM) in May 2024, triggering a comment period that closed in July 2024 with over 43,000 submissions.

Administrative law requires the DEA to review and respond to substantive comments before issuing a final rule. That review period, combined with potential requests for public hearings under 21 U.S.C. § 811(a), has stretched the process beyond the November 2026 election.

280E Tax Burden Persists

Cannabis businesses remain subject to Internal Revenue Code Section 280E, which prohibits deductions for businesses trafficking in Schedule I or II controlled substances. The cost? An estimated $1.8 billion annually in excess federal taxes. Rescheduling to Schedule III would eliminate that prohibition, allowing standard business expense deductions.

Operators will file 2026 tax returns under the current regime. Multi-state operators including Curaleaf, Trulieve, and Green Thumb Industries have cited 280E as a primary drag on profitability in recent earnings calls.

Research Access Still Gated

Schedule III classification would expand research access by reducing DEA registration requirements and removing NIDA's monopoly on federally legal cannabis supply for clinical trials. Current Schedule I status requires researchers to obtain both DEA and FDA authorization, a dual-approval process that's limited clinical studies to fewer than 200 active trials nationwide.

Universities and private research institutions have delayed protocol submissions pending the final rule, according to statements from the American Medical Association and the American Society of Addiction Medicine filed in the NPRM docket.

Legal Challenges Loom

Once the DEA issues a final rule, opponents will have 60 days to file petitions for review in federal appellate courts under the Administrative Procedure Act. Legal experts anticipate challenges from both prohibitionist groups arguing the rule is too permissive and reform advocates arguing Schedule III retains unnecessary restrictions.

Potential plaintiffs include:

• Smart Approaches to Marijuana (SAM), which submitted comments opposing any rescheduling
• State attorneys general from prohibition states
• Industry groups seeking full descheduling rather than rescheduling

Litigation could add 12-24 months. That's before a final enforceable rule takes effect.

State Programs Operate in Limbo

Forty-two states with medical or adult-use programs continue operating under the current Schedule I framework, creating a federal-state enforcement gap that rescheduling was intended to narrow. Banking access, interstate commerce, and federal employee participation remain restricted regardless of state law.

For full background on this process, see the CannIntel topic hub on DEA rescheduling.

Next procedural milestone: DEA publication of a final rule or notice of public hearing, expected no earlier than Q4 2026. Until then, the industry operates under a regulatory framework unchanged since the Controlled Substances Act took effect in 1970.